Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Jiangxi Key Laboratory of Clinical and Translational Cancer Research, Nanchang 330006, China.
Can J Gastroenterol Hepatol. 2023 Apr 26;2023:5492931. doi: 10.1155/2023/5492931. eCollection 2023.
The drug-eluting beads transarterial chemoembolization (DEB-TACE) has already been used in hepatic malignancies. We aim to evaluate the efficacy and safety of DEB-TACE in treating primary or secondary liver cancer.
We retrospectively evaluated 59 patients with hepatic malignancies, including 41 patients with primary liver cancer and 18 patients with secondary liver cancer, between September 2016 and February 2019. All patients were treated with DEB-TACE. Objective response rate (ORR) and disease control rate (DCR) were evaluated by mRECIST. The pain was assessed using a numerical rating scale (NRS) where 0 represented no pain, and a score of ten was unbearable. Adverse reactions were assessed according to Common Terminology Criteria for Adverse Events 4.0 (CTCAE4.0).
In the subgroup of primary liver cancer, 3 patients (7.32%) got complete response, 13 patients (31.71%) got partial response, 21 patients (51.22%) experienced stable disease, and 4 patients (9.76%) suffered progressive disease; ORR was 39.02% and DCR was 90.24%. In the subgroup of secondary liver cancer, 0 patients (0%) got complete response, 6 patients (33.33%) got partial response, 11 patients (61.11%) experienced stable disease, and 1 patient (5.56%) suffered progressive disease; ORR was 33.33% and DCR was 94.44%. We did not find any difference when comparing the efficacy between primary and secondary liver cancer (=0.612). The one-year survival rate was 70.73% for primary liver cancer and 61.11% for secondary liver cancer. There was no significant difference between the two groups (=0.52). For the patients with CR or PR, no factor could predict the efficacy of DEB-TACE. The most common treatment-related adverse reactions were short-term liver function disorders. The symptoms included fever (20.34%), abdomen pain (16.95%), and vomiting (5.08%), all patients with adverse reactions got remission after treatment.
DEB-TACE has a promising effect in the treatment of primary or secondary liver cancer. The treatment-related adverse reactions are tolerable.
载药微球动脉化疗栓塞术（DEB-TACE）已应用于肝脏恶性肿瘤。我们旨在评估 DEB-TACE 治疗原发性或继发性肝癌的疗效和安全性。
我们回顾性评估了 2016 年 9 月至 2019 年 2 月期间 59 例肝脏恶性肿瘤患者，其中原发性肝癌 41 例，继发性肝癌 18 例。所有患者均接受 DEB-TACE 治疗。采用 mRECIST 评估客观缓解率（ORR）和疾病控制率（DCR）。疼痛采用数字评分量表（NRS）评估，0 代表无痛，10 代表无法忍受。不良反应根据不良事件通用术语标准 4.0（CTCAE4.0）进行评估。
在原发性肝癌亚组中，3 例（7.32%）完全缓解，13 例（31.71%）部分缓解，21 例（51.22%）疾病稳定，4 例（9.76%）疾病进展；ORR 为 39.02%，DCR 为 90.24%。在继发性肝癌亚组中，0 例（0%）完全缓解，6 例（33.33%）部分缓解，11 例（61.11%）疾病稳定，1 例（5.56%）疾病进展；ORR 为 33.33%，DCR 为 94.44%。我们未发现原发性肝癌和继发性肝癌之间疗效存在差异（=0.612）。原发性肝癌患者的 1 年生存率为 70.73%，继发性肝癌为 61.11%。两组间无显著差异（=0.52）。对于 CR 或 PR 的患者，没有因素可以预测 DEB-TACE 的疗效。最常见的与治疗相关的不良反应是短暂的肝功能障碍。症状包括发热（20.34%）、腹痛（16.95%）和呕吐（5.08%），所有不良反应患者经治疗后均缓解。
DEB-TACE 治疗原发性或继发性肝癌疗效确切，治疗相关不良反应可耐受。
